Reasons for choosing our testing services
ZHONGXI Testing has obtained inspection qualification certifications from multiple countries and regions worldwide. We possess a senior testing team and advanced testing methods, providing independent, impartial, and professional third-party verification services for global carbon projects.
Internationally recognized authority
Certified by multiple international standards such as CNAS, VCS, and GS, with reports universally applicable worldwide.
Global service capability
Covering 140+ countries and regions, it supports on-site detection and remote verification in multiple languages.
Professional experimental methods
Adopt standard experimental methods to ensure accurate and reliable data.
Our Technical Capabilities: What We Detect and at What Depth
We employ multiparametric flow cytometry with up to 28 markers per tube on spectral and full‑spectrum cytometers (Cytek® Aurora and BD FACSymphony™). This allows us to identify all major and rare T‑cell subsets with single‑cell resolution, including:
- • Naïve (CD45RA+CCR7+), central memory (TCM), effector memory (TEM), terminal effector (TEMRA) subsets
- • Th1, Th2, Th17, Th9, Th22, Tfh (follicular helper) and regulatory T cells (Tregs: CD4+CD25+FoxP3+CD127low)
- • CD8+ subsets: naïve, memory, effector, and exhausted (PD‑1+, TIM‑3+, LAG‑3+)
- • Double‑negative (DN) T cells, double‑positive (DP) T cells, MAIT cells, iNKT cells, and γδ T cells (Vδ1, Vδ2 subpopulations)
For deeper resolution, we offer single‑cell RNA sequencing (scRNA‑seq) + TCR clonotyping (VDJ sequencing) on the 10x Genomics platform, revealing transcriptomic heterogeneity and clonal expansion status of up to 80,000 individual T cells per sample. Our standard flow cytometry panel detects subsets down to 0.01% of parent population with >99.5% reproducibility across replicates.
Overview of Detectable T‑Cell Subsets & Clinical Relevance
The table below summarizes the major T‑cell subsets we routinely identify, their key surface/intracellular markers, and associated clinical contexts.
| Subset | Key Markers (Human) | Clinical / Research Relevance |
|---|---|---|
| CD4+ T cells (helper) | CD3+CD4+ | HIV monitoring, autoimmune disease, vaccine response, primary immunodeficiency |
| Th1 | CXCR3+CCR6‑, T‑bet+, IFN‑γ+ | Intracellular infections, Crohn’s disease, anti‑tumor immunity |
| Th17 | CCR6+CD161+, RORγt+, IL‑17+ | Psoriasis, ankylosing spondylitis, multiple sclerosis, mucosal immunity |
| Treg | CD4+CD25+FoxP3+CD127low | Autoimmunity (deficiency), cancer (infiltration), transplantation tolerance |
| CD8+ cytotoxic T cells | CD3+CD8+ | Viral control, tumor surveillance, GvHD, immune aging |
| Exhausted CD8+ | PD‑1+TIM‑3+LAG‑3+ | Chronic viral infection (HIV, HCV), checkpoint blockade response |
| γδ T cells | TCRγδ+CD3+ | Innate‑like immunity, cancer immunotherapy, infectious diseases (tuberculosis) |
| MAIT cells | CD3+TCRVα7.2+CD161hi | Bacterial infection (MRSA, mycobacteria), autoimmune liver disease |
Beyond these, we provide activation markers (CD69, CD25, HLA‑DR, CD38), proliferation (Ki‑67), and intracellular cytokine staining (ICS) after in vitro stimulation – all standardized for whole blood, PBMCs, or tissue digests (e.g., tumor, synovial fluid, BAL).
Our Competitive Advantages in T‑Cell Subset Analysis
We distinguish ourselves by integrating high‑dimensional technical rigor with clinically oriented reporting and rapid turnaround. Key advantages include:
1. Broad panel flexibility & optimization – you are not limited to fixed panels. We design custom 18‑28 color panels to answer your specific hypothesis, including rare subsets (e.g., Treg expressing Helios, CD8+ Treg, T peripheral helper cells).
2. State‑of‑the‑art instrumentation – all assays run on spectral cytometers with automatic compensation and quality control (Spherotech beads, daily CS&T). This eliminates spectral overlap and enables detection of low‑abundance populations (<0.05% of CD3+).
3. Absolute quantitation – we provide both percentages and absolute cell counts per µL (using dual‑platform or volumetric counting), crucial for immunodeficiency and transplant monitoring.
4. High‑throughput and fast results – capacity for >200 samples per week; standard flow reports in 3‑5 business days; single‑cell + TCR sequencing in 14 days.
5. Expert interpretation & reference ranges – each report includes age‑matched reference ranges (neonates to elderly) and a clinical summary written by a board‑certified immunologist. We flag deviations that meet diagnostic criteria for conditions like DiGeorge syndrome (low recent thymic emigrants), IPEX (low Treg), or DOCK8 deficiency (Th17 loss).
6. Global sample logistics & stability validation – we provide Cyto‑Chex™ blood collection tubes that preserve T‑cell subset integrity for 72 hours at ambient temperature, enabling reliable analysis from remote sites. We also accept frozen PBMCs with pre‑stability validation.
7. Regulatory compliance – our laboratory is CLIA‑certified (CAP accredited) for clinical diagnostic testing, and our research services follow GDPR and HIPAA privacy standards. We can provide GCLP-compliant data for clinical trials.
Every T‑cell subset report is delivered as a PDF with high‑resolution gating strategy plots, heatmaps, and raw data tables (FCS files available on request). We also offer post‑analysis consultation to help you interpret the results in the context of your patient’s history or experimental design.
Ready to Characterize T‑Cell Subsets with Unparalleled Precision?
Whether you need a routine CD4 count, a 24‑parameter immune monitoring panel, or a full single‑cell atlas of tumor‑infiltrating lymphocytes, our T‑cell subset identification service is designed to meet your clinical or research needs. Order your test online in under 5 minutes, or contact our scientific team to design a custom panel. Samples can be shipped using our prepaid, temperature‑controlled kits. Turnaround starts as soon as samples arrive. Email immuno@precisioncytometry.com or call +1 (888) 707-8936 to initiate your analysis. We provide the depth, accuracy, and expertise you need – from rare subsets to full immune profiling.